tbuckley/cabot-search huggingface dataset:
Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
Authors: James E. Frampton, Stephen Silberstein
Journal: Drugs (2018)

The article OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine, written by James E. Frampton and Stephen Silberstein, was originally published Online First without open access. After publication in volume 78, issue 5, pages 589–600 [funder] requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by [funder]. Further details may be found at [MedEngine webpage link].
Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis
Authors: F. Poordad, S. Zeuzem, A. Asatryan, G. Foster, E. Gane, D. Wyles, P. Stanislas, M.B. Ferret, P. Kwo, T. Asselah, K.V. Kowdley, C. Hezode, K. Agarwal, S. Wang, N. Zadeikis, I.C. Ng, T. Pilot-Matias, Y. Lei, J. Kort, C.-W. Lin, F. Mensa
Journal: Journal of Hepatology (2018)
The hepatitis C continuum of care among HIV infected individuals in the Icona study network
Authors: E. Girardi, M. Puoti, C. Mussini, A. Tavelli, I. Mastrorosa, F.C. Silberstein, G. Madeddu, C. Molteni, P. Nasta, A. Antinori, A. D’arminio Monforte, A. Cozzi-Lepri
Journal: Journal of Hepatology (2018)
VOICE trial: Final results from multicenter phaseII study of assessment of clinical efficiency and safety in capecitabine plus intermittent oxaliplatin together with bevacizumab as first-line therapy for patients with advanced colorectal cancer.
Authors: Chihiro Kosugi, Keiji Koda, Tadamichi Denda, Keiichiro Ishibashi, Hideyuki Ishida, Kazuhiro Seike, Naoto Sakata, Shinji Yanagisawa, Akinari Miyazaki, Wataru Takayama, Naoto Koike, Hisahiro Matsubara, Masato Yamazaki, Hiroaki Shimizu, Kiyohiko Shuto, Mikito Mori, Kazuo Narushima
Journal: Journal of Clinical Oncology (2018)

740 Background: The FOLFOX with bevacizumab (B-mab) has been established as a standard first-line therapy for metastatic colorectal cancer (mCRC), and OPTIMOX1 study suggested that stop and go strategy for oxaliplatin reduced peripheral sensory neuropathy. The CapeOx is one of the standard treatments for mCRC that has been proven to be as effective as the FOLFOX regimen. Thus we accessed the efficacy and safety of the combination of intermittent CapeOx + B-mab as a first-line therapy in patients with mCRC in this trial. Methods: Eligibility criteria included ECOG PS: 0–1, No Peripheral neuropathy ( &lt; Grade 1). Patients received CapeOX (oxaliplatin 130mg/m 2 , capecitabine 2000mg/m 2 + B-mab 7.5mg/kg) q3 weeks for 5 cycles, maintenance without oxaliplatin for 5 cycles, and reintroduction CapeOX + B-mab for 5 cycles until progression. Primary endpoint was Progression Free Survival (PFS). Results: Between March 2011 and August 2013, 55 pts were enrolled. Baseline characteristics were median age of 67 years (range, 20–83); PS 0/1 (49/6 pts); male/female (33/22 pts), colon/rectum (28/27pts) and metastatic lesion liver/lung/lymph nodes (32/18/21 pts). A total of 47 pts were evaluated as Par Protocol Set population. 38 pts moved from initial CapeOX to maintenance Capecitabine. 20 pts moved to CapeOx reintroduction. Median PFS was 14.7months (95%CI, 8.6–19.5) and Median TTF was 12.3 months (95%CI, 10.3–14.3). Best overall response rate was 48.0%. Oxaliplatin reintroduction rate was 57.4%. Main grade 3/4 toxicity were: neutropenia (1 pt), anemia (1 pt), peripheral neuropathy (1 pt), allergic reaction of oxaliplatin (1 pt), deep vein thrombosis (1 pt), nausea (1 pt), hand-foot syndrome (1 pt), and hypertension (1 pt). Conclusions: This study met its primary endpoint PFS. CapeOx intermittent oxaliplatin indicated to reduce incidence of severe neutropenia and peripheral sensory neuropathy. The results suggested that our treatment strategy was well tolerate and effective for first line therapy in mCRC, and maintenance duration for 5 cycles, was reasonable. Clinical trial information: UMIN000005732.
Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 ( STAT1 )
Authors: Kornvalee Meesilpavikkai, Willem A. Dik, Benjamin Schrijver, Nicole M.A. Nagtzaam, Sandra J. Posthumus-van Sluijs, P. Martin van Hagen, Virgil A.S.H. Dalm
Journal: Journal of Allergy and Clinical Immunology (2018)
Impact of an antimicrobial stewardship policy on the reduction of empirical antibiotic treatment failure and the spread of multidrug-resistant organisms in hospitalized cirrhotic patients
Authors: S. Incicco, V.D. Gregorio, C. Lucidi, B. Lattanzi, D. D'ambrosio, D. Tavano, S.D. Cola, G. Ceccarelli, M. Venditti, M. Merli
Journal: Journal of Hepatology (2018)
P554Characterization of RNA-rich platelets by means of Cell Sorting and RNA-Sequencing
Authors: L Hille, M Cederqvist, C Stratz, B Gruening, V Benes, L Hein, F-J Neumann, D Trenk, T Nuehrenberg
Journal: Cardiovascular Research (2018)

in CON, reflected in an increased (P<0.05), while it had no effect in DMþHFDþCKD, suggesting that loss of NO was principally responsible for the perturbation in myocardial oxygen delivery in DMþHFDþCKD (Figure).This was supported by lower myocardial levels of NO2-þNO3in DMþHFDþCKD compared to CON (0.2060.02 vs 0.3460.06mmol/mg protein, P<0.05).Isolated vessels of DMþHFDþCKD swine showed decreased endothelial dependent vasodilation to BK, mediated via a complete abolishment of the NO-dependent vasodilator pathway, consistent with the in vivo observations.Conclusion: Prolonged exposure to DM, HFD and CKD results in a pro-inflammatory state associated with impaired coronary microvascular NO production, thereby altering coronary microvascular dilation and hampering myocardial perfusion.
Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria
Authors: Michael J. Clemente, Bartlomiej Przychodzen, Cassandra M. Hirsch, Yasunobu Nagata, Taha Bat, Marcin W. Wlodarski, Tomas Radivoyevitch, Hideki Makishima, Jaroslaw P. Maciejewski
Journal: Leukemia (2018)
Irish woman is awarded €2.5m from US laboratory that missed cervical cancer
Authors: Clare Dyer
Journal: BMJ (2018)

The case of an Irish woman who has won a €2.5m (£2.2m; $3m) settlement over an incorrect smear test reading by a US laboratory to which the task was outsourced has sparked a nationwide scandal.

Vicky Phelan’s smear was wrongly labelled negative in 2011, and she now has terminal cervical cancer. She reached the settlement with Clinical Pathology Laboratories, based in Texas.

An audit of the smear test results of women who later developed cervical cancer found that some of those labelled negative featured abnormalities that should have been acted on at the time. But the women whose earlier results were wrongly labelled were not told when the mistake was discovered, and some have died without learning of the errors. Another 10 women are …
Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion
Authors: William L. Heaton, Anna V. Senina, Anthony D. Pomicter, Mohamed E. Salama, Phillip M. Clair, Dongqing Yan, Russell N. Bell, Jeremy M. Gililland, Josef T. Prchal, Thomas O’Hare, Michael W. Deininger
Journal: Leukemia (2018)

Tumor necrosis factor alpha (TNF) is increased in myelofibrosis (MF) and promotes survival of malignant over normal cells. The mechanisms altering TNF responsiveness in MF cells are unknown. We show that the proportion of marrow (BM) cells expressing TNF is increased in MF compared to controls, with the largest differential in primitive cells. Blockade of TNF receptor 2 (TNFR2), but not TNFR1, selectively inhibited colony formation by MF CD34+ and mouse JAK2V617F progenitor cells. Microarray of mouse MPN revealed reduced expression of X-linked inhibitor of apoptosis (Xiap) and mitogen-activated protein kinase 8 (Mapk8) in JAK2V617F relative to JAK2WT cells, which were normalized by TNFR2 but not TNFR1 blockade. XIAP and MAPK8 were also reduced in MF CD34+ cells compared to normal BM, and their ectopic expression induced apoptosis. Unlike XIAP, expression of cellular IAP (cIAP) protein was increased in MF CD34+ cells. Consistent with cIAP's role in NF-κB activation, TNF-induced NF-κB activity was higher in MF vs. normal BM CD34+ cells. This suggests that JAK2V617F reprograms TNF response toward survival by downregulating XIAP and MAPK8 through TNFR2. Our results reveal an unexpected pro-apoptotic role for XIAP in MF and identify TNFR2 as a key mediator of TNF-induced clonal expansion.
Baseline neutrophil-to-lymphocyte ratio in patients with advanced melanoma treated with immune checkpoint inhibitors: reply from the authors
Authors: Y. Fujisawa
Journal: British Journal of Dermatology (2018)

Linked Articles:Machet et al. Br J Dermatol 2018 179:224. Fujisawa et al. Br J Dermatol 2018; 179:213–215.
Anticholinergic drugs and risk of dementia: case-control study
Authors: Kathryn Richardson, Chris Fox, Ian Maidment, Nicholas Steel, Yoon K Loke, Antony Arthur, Phyo K Myint, Carlota M Grossi, Katharina Mattishent, Kathleen Bennett, Noll L Campbell, Malaz Boustani, Louise Robinson, Carol Brayne, Fiona E Matthews, George M Savva
Journal: BMJ (2018)

To estimate the association between the duration and level of exposure to different classes of anticholinergic drugs and subsequent incident dementia.Case-control study.General practices in the UK contributing to the Clinical Practice Research Datalink.40 770 patients aged 65-99 with a diagnosis of dementia between April 2006 and July 2015, and 283 933 controls without dementia.Daily defined doses of anticholinergic drugs coded using the Anticholinergic Cognitive Burden (ACB) scale, in total and grouped by subclass, prescribed 4-20 years before a diagnosis of dementia.Odds ratios for incident dementia, adjusted for a range of demographic and health related covariates.14 453 (35%) cases and 86 403 (30%) controls were prescribed at least one anticholinergic drug with an ACB score of 3 (definite anticholinergic activity) during the exposure period. The adjusted odds ratio for any anticholinergic drug with an ACB score of 3 was 1.11 (95% confidence interval 1.08 to 1.14). Dementia was associated with an increasing average ACB score. When considered by drug class, gastrointestinal drugs with an ACB score of 3 were not distinctively linked to dementia. The risk of dementia increased with greater exposure for antidepressant, urological, and antiparkinson drugs with an ACB score of 3. This result was also observed for exposure 15-20 years before a diagnosis.A robust association between some classes of anticholinergic drugs and future dementia incidence was observed. This could be caused by a class specific effect, or by drugs being used for very early symptoms of dementia. Future research should examine anticholinergic drug classes as opposed to anticholinergic effects intrinsically or summing scales for anticholinergic exposure.Registered to the European Union electronic Register of Post-Authorisation Studies EUPAS8705.
META-ANALYSIS SHOWS THAT THE SECOND INSPECTION OF THE PROXIMAL COLON INCREASES ADENOMA DETECTION RATE
Authors: K Triantafyllou, P Gkolfakis, G Tziatzios, L Fuccio, C Hassan
Journal: Endoscopy (2018)

There is evidence that a second examination of the proximal colon (PC) increases the diagnostic yield of colonoscopy. The aim of this meta-analysis was to examine the incremental benefit of a second, back-to-back mucosa inspection of the PC.
Amplifying Apoptosis Homing Nanoplatform for Tumor Theranostics
Authors: Heng Zhao, Ping Zhou, Kai Huang, Guang Deng, Zhiguo Zhou, Jing Wang, Mingwei Wang, Yingjian Zhang, Hong Yang, Shiping Yang
Journal: Advanced Healthcare Materials (2018)

Abstract Nanomedicine has significantly impacted cancer theranostics. However, its efficiency is restricted by the limited enhanced permeability and retention effect of nanomaterials and insufficient density/specificity of receptors of tumor cells. Herein, an apoptosis‐homing nanoplatform based on zinc(II) dipicolylamine (ZnDPA) conjugated Fe/Fe 3 O 4 nanoparticles (MNPs/ZnDPA), which demonstrates amplified magnetic resonance signal and photothermal therapy, is developed. In an apoptotic xenograft model constructed by doxorubicin, due to the high affinity between ZnDPA and the upregulated level of phosphatidylserine on the outer surface of apoptotic cancer cells, the accumulation value of MNPs/ZnDPA is enhanced two‐fold and the tumor/muscle ratio of T 2 values is decreased to 50% compared to that in the normal xenograft model. In the apoptotic xenograft model, the amplifying photothermal therapy is confirmed by the changes of the relative tumor volume and terminal deoxynucleotidyl transferase‐mediated dUTP‐biotin nick end‐labeling staining. This nanoplatform provides a promising strategy to improve the targeting efficiency of nanoparticles and the enhancement of tumor‐targeting theranostics.
Recombinant amelogenin regulates the bioactivity of mouse cementoblasts in vitro
Authors: Sema S. Hakki, S. Buket Bozkurt, Emre Türkay, Michel Dard, Nuhan Purali, Werner Götz
Journal: International Journal of Oral Science (2018)

Abstract Amelogenin (AMG) is a cell adhesion molecule that has an important role in the mineralization of enamel and regulates events during dental development and root formation. The purpose of the present study was to investigate the effects of recombinant human AMG (rhAMG) on mineralized tissue-associated genes in cementoblasts. Immortalized mouse cementoblasts (OCCM-30) were treated with different concentrations (0.1, 1, 10, 100, 1000, 10,000, 100,000 ng · mL -1 ) of recombinant human AMG (rhAMG) and analyzed for proliferation, mineralization and mRNA expression of bone sialoprotein (BSP), osteocalcin (OCN), collagen type I (COL I), osteopontin (OPN), runt-related transcription factor 2 (Runx2), cementum attachment protein (CAP), and alkaline phosphatase (ALP) genes using quantitative RT-PCR. The dose response of rhAMG was evaluated using a real-time cell analyzer. Total RNA was isolated on day 3, and cell mineralization was assessed using von Kossa staining on day 8. COL I, OPN and lysosomal-associated membrane protein-1 (LAMP-1), which is a cell surface binding site for amelogenin, were evaluated using immunocytochemistry. F-actin bundles were imaged using confocal microscopy. rhAMG at a concentration of 100,000 ng · mL -1 increased cell proliferation after 72 h compared to the other concentrations and the untreated control group. rhAMG (100,000 ng · mL -1 ) upregulated BSP and OCN mRNA expression levels eightfold and fivefold, respectively. rhAMG at a concentration of 100,000 ng · mL -1 remarkably enhanced LAMP-1 staining in cementoblasts. Increased numbers of mineralized nodules were observed at concentrations of 10,000 and 100,000 ng · mL -1 rhAMG. The present data suggest that rhAMG is a potent regulator of gene expression in cementoblasts and support the potential application of rhAMG in therapies aimed at fast regeneration of damaged periodontal tissue.
Genetic Lineage Tracing of Nonmyocyte Population by Dual Recombinases
Authors: Yan Li, Lingjuan He, Xiuzhen Huang, Shirin Issa Bhaloo, Huan Zhao, Shaohua Zhang, Wenjuan Pu, Xueying Tian, Yi Li, Qiaozhen Liu, Wei Yu, Libo Zhang, Xiuxiu Liu, Kuo Liu, Juan Tang, Hui Zhang, Dongqing Cai, Adams H. Ralf, Qingbo Xu, Kathy O. Lui, Bin Zhou
Journal: Circulation (2018)

Whether the adult mammalian heart harbors cardiac stem cells for regeneration of cardiomyocytes is an important yet contentious topic in the field of cardiovascular regeneration. The putative myocyte stem cell populations recognized without specific cell markers, such as the cardiosphere-derived cells, or with markers such as Sca1+, Bmi1+, Isl1+, or Abcg2+ cardiac stem cells have been reported. Moreover, it remains unclear whether putative cardiac stem cells with unknown or unidentified markers exist and give rise to de novo cardiomyocytes in the adult heart.To address this question without relying on a particular stem cell marker, we developed a new genetic lineage tracing system to label all nonmyocyte populations that contain putative cardiac stem cells. Using dual lineage tracing system, we assessed whether nonmyocytes generated any new myocytes during embryonic development, during adult homeostasis, and after myocardial infarction. Skeletal muscle was also examined after injury for internal control of new myocyte generation from nonmyocytes.By this stem cell marker-free and dual recombinases-mediated cell tracking approach, our fate mapping data show that new myocytes arise from nonmyocytes in the embryonic heart, but not in the adult heart during homeostasis or after myocardial infarction. As positive control, our lineage tracing system detected new myocytes derived from nonmyocytes in the skeletal muscle after injury.This study provides in vivo genetic evidence for nonmyocyte to myocyte conversion in embryonic but not adult heart, arguing again the myogenic potential of putative stem cell populations for cardiac regeneration in the adult stage. This study also provides a new genetic strategy to identify endogenous stem cells, if any, in other organ systems for tissue repair and regeneration.
Resequencing of 243 diploid cotton accessions based on an updated A genome identifies the genetic basis of key agronomic traits
Authors: Xiongming Du, Gai Huang, Shoupu He, Zhaoen Yang, Gaofei Sun, Xiongfeng Ma, Nan Li, Xueyan Zhang, Junling Sun, Min Liu, Yinhua Jia, Zhaoe Pan, Wenfang Gong, Zhaohui Liu, Heqin Zhu, Lei Ma, Fuyan Liu, Daigang Yang, Fan Wang, Wei Fan, Qian Gong, Zhen Peng, Liru Wang, Xiaoyang Wang, Shuangjiao Xu, Haihong Shang, Cairui Lu, Hongkun Zheng, Sanwen Huang, Tao Lin, Yuxian Zhu, Fuguang Li
Journal: Nature Genetics (2018)
Abstract 18697: Should Aggressive Implantation of a Temporary Rvad Be Utilized as Means of Recovery for Rv Function to Allow for Long-Term Left Ventricular Assist Device Therapy
Authors: Ann C Gaffey, Carol W Chen, Jason Han, J E Rame, Michael S Kiernan, Jennifer Chung, Susan L Myers, Francisco A Arabia, Robert K Kormos, Mark S Slaughter, David C Naftel, Andrew J Cucchiara, Michael A Acker, Pavan Atluri
Journal: Circulation (2016)

Continuous flow left ventricular assist device (LVAD) is an ideal treatment for end-stage heart failure, but right ventricular dysfunction has classically been a contraindication for long term LVAD...
Apoptotic cell–induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans
Authors: Rahul Shinde, Kebria Hezaveh, Marie Jo Halaby, Andreas Kloetgen, Ankur Chakravarthy, Tiago da Silva Medina, Reema Deol, Kieran P. Manion, Yuriy Baglaenko, Maria Eldh, Sara Lamorte, Drew Wallace, Sathi Babu Chodisetti, Buvana Ravishankar, Haiyun Liu, Kapil Chaudhary, David H. Munn, Aristotelis Tsirigos, Michael Madaio, Susanne Gabrielsson, Zahi Touma, Joan Wither, Daniel D. De Carvalho, Tracy L. McGaha
Journal: Nature Immunology (2018)
KRAS/NRAS/BRAF genotyping in patients with mestastatic colorectal cancer.
Authors: Nuria Rodriguez Salas, Jesus Miranda, Lorena Ostios, Mario Muñoz, Alberto Borobia, Gema Gordo, Jair Tenorio, Hoi Tong, Maria Teresa García Morales, Jose Carlos Martinez Avila
Journal: Journal of Clinical Oncology (2018)

718 Background: mCRC is the 2º cause of death in the world. Development of targeted therapies has increased the survival. The efficacy of these drugs (such Bevacizumab and monoclonal antibodies against EGFR) depends on the use of genetic biomarkers such as KRAS and NRAS. The BRAF status acts as prognostic factor. The objective of this study was to perform a mutational analysis of KRAS/NRAS/BRAF in a cohort of 326 Spanish patients, and correlate the findings with clinical factors. Methods: We analyzed KRAS by chip-array analysis (Infiniti System, USA), NRAS using pyrosequencing on a Pyromark Q96MD instrument (Qiagen, USA) and BRAF mutations (in 80 of these samples) by means of Infiniti System (AutoGenomics, USA). Results: KRAS mutations 129/326 patients had KRAS mutation (31.2% in codon 12 and 6.7% in codon 13). The median age was 68.9, 55% male, 66.4% had left-sided tumor, 83% histologically grade 2 tumor. The pattern of spread was liver (51.1%), lung (33.3%) and peritoneum (11.6%). There were 6 types of mutation in codon 12 (p.Gly12Asp, p.Gly12Cys, p.Gly12Val, p.Gly12Arg, p.Gly12Ser, p.Gly12Ala) and 1 type in codon 13 (p.Gly13Asp). We apply a logistic model (age&amp;sex corrected) to location, and we found association between KRAS wild type and left location, OR 1.73 [CI:1.03-2.9] p = 0.035 NRAS mutations: 13 patients had NRAS mutation (3.98%), 8 male, 92% had left-sided, 46% liver metastasis and 53.9% lung metastasis. Type of NRAS mutation: 1.6% in exon 2 (1.2% in codon 12 and 0.4% in codon 13) and 1.8% in exon 3 (0.2% in codon 59 and 1.6% in codon 61). In exon 2 we found 2 types of changes, 1 in codon 12 (p.Gly12Asp) and 1 in codon 13 (p.Gly13Arg). In exon 3 we found 5 types of changes, 1 in codon 59 (p.Ala59Thr) and 4 in codon 61 (p.Gln61Glu; p.Gln61Leu; p.Gln61Arg; p.Gln61His). BRAF mutation: 9/80 patients harboured mutations, all of them at the residue V600E. Conclusions: In our cohort 39.5% had mutations in KRAS, 3.98% in NRAS and 11% in BRAF. KRAS mutation is associated to right-sided location.
A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics
Authors: Laurent Claret, Jin Y. Jin, Charles Ferté, Helen Winter, Sandhya Girish, Mark Stroh, Pei He, Marcus Ballinger, Alan Sandler, Amita Joshi, Achim Rittmeyer, David Gandara, Jean-Charles Soria, René Bruno
Journal: Clinical Cancer Research (2018)

Purpose: Standard endpoints often poorly predict overall survival (OS) with immunotherapies. We investigated the predictive performance of model-based tumor growth inhibition (TGI) metrics using data from atezolizumab clinical trials in patients with non-small cell lung cancer.Patients and Methods: OS benefit with atezolizumab versus docetaxel was observed in both POPLAR (phase II) and OAK (phase III), although progression-free survival was similar between arms. A multivariate model linking baseline patient characteristics and on-treatment tumor growth rate constant (KG), estimated using time profiles of sum of longest diameters (RECIST 1.1) to OS, was developed using POPLAR data. The model was evaluated to predict OAK outcome based on estimated KG at TGI data cutoffs ranging from 10 to 122 weeks.Results: In POPLAR, TGI profiles in both arms crossed at 25 weeks, with more shrinkage with docetaxel and slower KG with atezolizumab. A log-normal OS model, with albumin and number of metastatic sites as independent prognostic factors and estimated KG, predicted OS HR in subpopulations of patients with varying baseline PD-L1 expression in both POPLAR and OAK: model-predicted OAK HR (95% prediction interval), 0.73 (0.63-0.85), versus 0.73 observed. The POPLAR OS model predicted greater than 97% chance of success of OAK (significant OS HR, P < 0.05) from the 40-week data cutoff onward with 50% of the total number of tumor assessments when a successful study was predicted from 70 weeks onward based on observed OS.Conclusions: KG has potential as a model-based early endpoint to inform decisions in cancer immunotherapy studies. Clin Cancer Res; 24(14); 3292-8. ©2018 AACR.
Glucose Homeostasis Is Important for Immune Cell Viability during Candida Challenge and Host Survival of Systemic Fungal Infection
Authors: Timothy M. Tucey, Jiyoti Verma, Paul F. Harrison, Sarah L. Snelgrove, Tricia L. Lo, Allison K. Scherer, Adele A. Barugahare, David R. Powell, Robert T. Wheeler, Michael J. Hickey, Traude H. Beilharz, Thomas Naderer, Ana Traven
Journal: Cell Metabolism (2018)
Accurate prediction of clinical disease progression in patients with advanced fibrosis due to NASH using a Bayesian machine learning approach
Authors: J.C. Latourelle, J. Tu, R.K. Das, L. Furchtgott, B. Schoeberl, B. Smiechowski, B.W. Church, I.G. Khalil, B. Hayete, S. Djedjos, T. Nguyen, Y. Xiao, R.A. Schall, G. Chen, M. Subramanian, R. Myers, V. Ratziu, N. Afdhal, J. Bosch, Z. Goodman, S. Harrison, A. Sanyal
Journal: Journal of Hepatology (2018)